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cell transplantation (HSCT) recipients has led to increased
incidence of mucormycosis and emergence of drug resistant
fungi. We report the development of arthritis by a rare
fungus, Colletotrichum coccodes, under posaconazole pro-
phylaxis, probable voriconazole-resistant aspergillosis, and
mucormycosis by Cunninghamella species in a HSCT recip-
ient with protracted graft versus host disease (GvHD).
A 60-year-old man with Stage IV peripheral T-cell lym-
phoma, underwent an allogeneic HSCT fromapartially human
leukocyte antigen (HLA)-matched (8/10) sibling donor, after a
reduced-intensity conditioning regimen consisting of fludar-
abine, cyclophosphamide, and total body irradiation.
Antithymocyte globulin, cyclosporine, and mycophenolate
mofetil were GvHD prophylaxis. Neutrophil engraftment was
confirmed on Day 9 and post-transplant marrow examination
revealed complete donor chimerism with nominimal residual
disease. Over the next 2 months, several episodes of biopsy-
confirmed GvHD of the gut developed, and pulse methyl-
prednisolone and etanercept were given. Prophylactic pos-
aconazole was administered and substituted with
amphotericin B deoxycholate (AmBd) 1 month later when
joint abscess developed over his second and thirdConflicts of interest: The authors have no conflicts of interest
relevant to this article.
* Corresponding author. Department of Internal Medicine, Na-
tional Taiwan University Hospital, 7 Chung-Shan South Road, Taipei
100, Taiwan.
E-mail address: hysun13@gmail.com (H.-Y. Sun).
http://dx.doi.org/10.1016/j.jfma.2015.03.008
0929-6646/Copyright ª 2015, Formosan Medical Association. Published
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/metapharyngeal joints. Culture of the aspirated fluid yielded
Colletotrichum coccodes. The patient was put on mainte-
nance voriconazole due to Type 1 renal tubular acidosis after
44 days of AmBd. One month later, the patient was tested
positive for galactomannan (GM) antigen during readmission
for recurrent GvHD. Chest computed tomography revealed a
cavitary lesion with surrounding satellite opacity at the left
lower lobe. SubsequentGM levels increased despite adequate
vorionazole levels. After the addition of liposomal ampho-
tericin B, GM titers declined, but the patient’s condition
deteriorated. The patient died of septic shock andmultiorgan
failure on Dayþ260 post-HSCT. Cunninghamella species grew
from his bronchial washing specimen with high minimum
inhibitory concentration of >8 mg/L at 48 hours to vor-
iconazole, posaconazole, and AmBd.
Colletotrichum is a rare opportunistic fungal pathogen
with only a few cases of keratitis reported. Its treatment
remains uncertain whereas AmBd, ketoconazole, flucyto-
sine, and itraconazole have all been reported to be variably
effective. Posaconazole exhibited potent antifungal activ-
ities against a variety of medically important fungi, pre-
vented mycosis more effectively than did either fluconazole
or itraconazole, and improved overall survival in patients
undergoing remissioneinduction chemotherapy for acute
myelogenous leukemia or myelodysplastic syndromes.1
As routine prophylaxis with posaconazole in high-risk pa-
tients has become common, evolving fungal epidemiology
under selection pressure has developed. A study illustrated a
shift in fungal epidemiology to non-Aspergillus spp., partic-
ularly by the class Zygomycetes, following introduction of
posaconazole.2 Such an observation possibly resulted fromby Elsevier Taiwan LLC. This is an open access article under the
4.0/).
Breakthrough invasive fungal infection 385the poor absorption of posaconazole due to mucositis after
chemotherapy or GvHD. Another study showed patients with
hematologic malignancy receiving voriconazole were vulner-
able tomucormycosis.3 It is also speculated that pre-exposure
of molds colonizing the respiratory tract (especially Asper-
gillus) to posaconazole would result in a lack of fungicidal
activity of subsequent voriconazole-based treatment.4
Despite the expanding armamentarium of antifungal
agents, our war with fungi does not cease. With the
enlarging population of immunocompromised hosts and
evolving epidemiology of mycosis, prompt identification of
causative pathogens is more critical than ever to optimize
the use of antifungal agents.
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